CD274 and neoplasm: In a previous study, we demonstrated the additive anti-tumor effect of a bispecific Nanofitin, engineered by the genetic assembly of the two Nanofitin modules B11 and A-C2, respectively, enabling the neutralization of the immune checkpoint PDL1 and the polarization of tumour-associated macrophages to the anti-tumoral M1-like phenotype [13].